Yarrow Bioscience CMO option holdings disclosed
Yarrow Bioscience, Inc. reports initial beneficial ownership for Chief Medical Officer Steven Ryder.
Rhea-AI Filing Summary
Yarrow Bioscience, Inc. reports initial beneficial ownership for Chief Medical Officer Steven Ryder. He holds a stock option to purchase 228,330 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on 2036-04-17.
The option was received in connection with the merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged with Yarrow and VYNE changed its name to Yarrow Bioscience, Inc. One quarter of the option will vest on April 8, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ryder Steven
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 228,330 contracts (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 228,330 shares of Issuer Common Stock, one quarter of which will vest on April 8, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Option underlying shares: 228,330 shares
Option exercise price: $6.19 per share
Option expiration date: 2036-04-17
+2 more
5 metrics
Option underlying shares
228,330 shares
Right to purchase Issuer Common Stock reported for Steven Ryder as of 2026-07-27
Option exercise price
$6.19 per share
Exercise price of the reported stock option
Option expiration date
2036-04-17
Expiration date of the reported stock option
Initial vesting date
April 8, 2027
One quarter of the option vests on this date, with remaining vesting monthly over three years
Par value of Issuer Common Stock
$0.0001
Par value of Issuer Common Stock underlying the option
Key Terms
Effective Time, Merger, Issuer Common Stock, vest, +1 more
5 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
Merger regulatory
"a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
Issuer Common Stock financial
"Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock")"
vest financial
"one quarter of which will vest on April 8, 2027, with the remaining three quarters"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service financial
"vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Form 3 reveal for Yarrow Bioscience (VYNE)?
It shows Chief Medical Officer Steven Ryder’s initial holding of stock options for 228,330 shares of Issuer Common Stock at a $6.19 exercise price, expiring 2036-04-17, with vesting beginning in 2027 following the VYNE–Yarrow merger and name change.
What are the key terms of Steven Ryder’s Yarrow Bioscience (VYNE) option grant?
The option gives Ryder the right to buy 228,330 shares at an exercise price of $6.19 per share, expiring on 2036-04-17. It was assumed in the merger and maintains the same terms and conditions that applied to his prior Yarrow options.
When do Steven Ryder’s Yarrow Bioscience (VYNE) options begin vesting?
Vesting starts on April 8, 2027, when one quarter of the option vests. The remaining three quarters vest in equal monthly installments over the following three years, conditioned on Ryder’s continued service with Yarrow Bioscience on each vesting date.
How did the VYNE–Yarrow merger affect Steven Ryder’s equity in VYNE?
At the merger’s Effective Time, Ryder’s existing Yarrow options were assumed and converted into options for Issuer Common Stock. Each option now represents rights to shares of the renamed Yarrow Bioscience, Inc., preserving the pre-merger terms, including vesting and expiration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
